Form 4: Stoke Therapeutics GC Sells Shares Post-RSU Vesting

Stoke Therapeutics' General Counsel, Jonathan Allan, reported the vesting of restricted stock units and subsequent sales of common stock to cover tax withholding liabilities.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported transactions involving company common stock.
• On December 1, 2025, 12,357 restricted stock units (RSUs) vested, converting into common stock at a price of $0.
• Following the vesting, Allan's direct beneficial ownership of common stock increased to 24,188 shares.
• Between December 2 and December 3, 2025, Allan sold a total of 4,576 shares of common stock.
• These sales were mandated by the Issuer to satisfy tax withholding liabilities associated with the RSU vesting.
• The sales occurred at weighted average prices ranging from $29.562 to $30.8477 per share.
• After these transactions, Allan's direct beneficial ownership of common stock stands at 19,612 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation events (RSU vesting) and subsequent sales to cover tax liabilities, which is a neutral event. The pre-planned nature (10b5-1 plan) mitigates any negative sentiment from the sales.

Positives

• The vesting of 12,357 restricted stock units indicates continued compensation and retention of a key executive.
• The transactions were executed under a Rule 10b5-1(c) plan, suggesting pre-planned and not opportunistic sales.

Negatives

• The executive sold 4,576 shares of common stock, reducing their direct beneficial ownership.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general implication of executive share sales, which are explicitly stated to be for tax withholding.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing details routine executive compensation and tax-related share sales, which are common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends or competitive positioning for Stoke Therapeutics.

Comparison to Industry Standards

• This filing reports standard executive compensation practices involving restricted stock unit vesting and subsequent sales to cover tax obligations, which is a common and accepted practice across publicly traded companies globally. No specific comparable companies, projects, or results are mentioned in the filing to allow for a detailed comparison.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting (already accounted for in compensation plans) and a slight reduction in insider ownership, offset by the routine nature of tax-related sales.
• Employees: The vesting of RSUs demonstrates the company's compensation structure for executives.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive's restricted stock units vested, and a portion of the resulting shares were sold to cover tax withholding liabilities. These sales were pre-planned under a Rule 10b5-1(c) plan, indicating they were not discretionary or based on new material information. Such transactions are common and generally do not signal a change in the company's fundamentals or the executive's confidence. Therefore, the filing itself does not provide a basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate, maintaining existing positions based on broader company performance and market conditions.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Jonathan Allan, Restricted Stock Units, RSU Vesting, Share Sale, Executive Compensation, Tax Withholding